Panacea Biotech share price has zoomed 5% and is presently trading at Rs 380.4.
Meanwhile, the BSE HEALTHCARE index is at 43,973.8 (up 0.3%).
Among the top gainers in the BSE HEALTHCARE index today are Procter & Gamble Health (up 6.6%) and GLAND PHARMA (up 3.4%).
FORTIS HEALTHCARE (down 2.4%) and MAX HEALTHCARE INSTITUTE (down 1.9%) are among the top losers today.
Over the last one year, Panacea Biotech has moved up from Rs 149.5 to Rs 380.4, registering a gain of Rs 230.9 (up 154.5%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,350.0 to 43,973.8, registering a gain of 60.8% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 229.2%), SUVEN PHARMACEUTICALS (up 130.2%) and Glenmark Pharma (up 129.8%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 78,791.1 .
The top gainers among the BSE Sensex today are JSW Steel (up 1.9%) and Tata Steel (up 1.6%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 23,983.7 (down 0.1%). Coal India and MUNDRA PORT & SEZ are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 63,591.3 to 78,791.1, registering a gain of 15,199.8 points (up 23.9%).
Panacea Biotech net profit fell 244.6% YoY to Rs -159 million for the quarter ended June 2024, compared to a profit of Rs 110 million a year ago. Net sales declined 10.4% to Rs 1,157 million during the period as against Rs 1,292 million in April-June 2023.
For the year ended March 2024, Panacea Biotech reported 95.5% increase in net profit to Rs -15 million compared to net loss of Rs 337 million during FY23. Revenue of the company grew 21.6% to Rs 5,592 million during FY24.
The current Price to earnings ratio of Panacea Biotech, based on rolling 12 month earnings, stands at -82.1.
Equitymaster requests your view! Post a comment on "Panacea Biotech Gains 5%; BSE HEALTHCARE Index Up 0.3%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!